News - Pradaxa, Alnylam Pharmaceuticals

Filter

Popular Filters

1 to 25 of 42 results

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Alnylam to acquire Merck’s Sirna Therapeutics

Alnylam to acquire Merck’s Sirna Therapeutics

13-01-2014

US RNAi therapeutics specialist Alnylam Pharmaceuticals says it has reached agreement to acquire US pharma…

Alnylam PharmaceuticalsBiotechnologyMerck & CoMergers & AcquisitionsSirna Therapeutics

Boehringer analysis finds better outcome for Pradaxa compared to warfarin

Boehringer analysis finds better outcome for Pradaxa compared to warfarin

08-10-2013

Boehringer Ingelheim has released new data showing better survival prognosis following a major bleeding…

Boehringer IngelheimHematologyPharmaceuticalPradaxaResearch

Ph I cholesterol lowerer offers new hope for patients resistant to statins

04-10-2013

A study published in The Lancet found that participants in a Phase I clinical trial saw their level of…

ALN-PCSAlnylam PharmaceuticalsBiotechnologyCardio-vascularResearch

Boehringer Ingelheim plans to expand body of evidence for Pradaxa

04-09-2013

German family-owned drug major Boehringer Ingelheim has announced new milestones for the novel oral anticoagulant…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

Pradaxa sNDA for DVT and PE accepted by FDA

28-08-2013

The US Food and Drug Administration has accepted for review German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

FDA confirms views that Boehringer's Pradaxa bleeding rates no higher than for warfarin

19-03-2013

A new perspective from the US Food and Drug Administration states the agency has not changed its recommendations…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaResearch

Positive trials results for Boehringer Ingelheim's Pradaxa for prevention of recurrent DVT and PE

22-02-2013

Findings from the RE-MEDY and RE-SONATE trials investigating German family-owned drug major Boehringer…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

The Medicines Company gets rights to Alnylam's PCSK9 inhibitors program for cholesterol

05-02-2013

USA-based The Medicines Company (Nasdaq: MDCO) has formed an exclusive global alliance with RNAi therapeutics…

Alnylam PharmaceuticalsAngiomaxBiotechnologyCardio-vascularLicensingPharmaceuticalThe Medicines Company

Boehringer Ingelheim updates safety info for Pradaxa related to heart valve

21-12-2012

The US subsidiary of German independent drug major Boehringer Ingelheim says that the US prescribing…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Australian review finds more work needed on new anticoagulants

19-12-2012

A report into anticoagulation therapies released yesterday by Australian Minister for Health Tanya Plibersek…

Asia-PacificBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulation

Highlights from ASH meeting on Eliquis, Pradaxa, ALN-TMP and ibrutinib

11-12-2012

During the 54th Annual Meeting of the American Society of Hematology (ASH) now taking place in Atlanta,…

ALN-TMPAlnylam PharmaceuticalsBiotechnologyBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisibrutinibOncologyPfizerPharmaceuticalPharmacyclicsPradaxaResearch

Alnylam and Tekmira restructure relationship and settle all litigation in $65 million deal

14-11-2012

USA-based Alnylam Pharmaceuticals (Nasdaq: ALNY) says it has restructured its relationship with Canadian…

Alnylam PharmaceuticalsBiotechnologyFinancialLegalLicensingPharmaceuticalTekmira Pharmaceuticals

Serious bleeding risk with Boehringer's Pradaxa no worse than warfarin, says FDA

06-11-2012

In a follow up to a 2011 safety communication, the US Food and Drug Administration has evaluated new…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationResearch

Alnylam gets upfront $22.5 million in RNAi link with Genzyme

23-10-2012

French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

Early-stage cholesterol drug offers new hope for patients resistant to statins

03-10-2012

A study published in The Lancet found that participants in a Phase I clinical trial saw their level of…

ALN-PCSAlnylam PharmaceuticalsBiotechnologyCardio-vascularResearch

Pradaxa efficacy and cost effectiveness advantages over Xarelto

27-08-2012

Indirect comparison based on the RE-LYtrial (for family owned German drugmaker Boehringer Ingelheim's…

BayerBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingResearchXarelto

Silencing investor concerns? Alnylam achieves RNAi milestone

02-08-2012

US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone…

Alnylam PharmaceuticalsAnti-viralsBiotechnologyFinancialGlaxoSmithKlineLicensingProductionVaccines

Alnylam and Ascletis collaborate to develop ALN-VSP for liver cancers in China

15-07-2012

US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) and Ascletis Pharmaceuticals,…

ALN-VSPAlnylam PharmaceuticalsAscletis PharmaceuticalsAsia-PacificBiotechnologyLicensingOncology

1 to 25 of 42 results

Company Spotlight

Fibrotech

Fibrotech

Back to top